Bottom Line: In patients with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and immunotherapy made tumors more amenable to surgery ...

Citation: Trial finds adding immunotherapy to neoadjuvant chemoradiation may improve outcomes in esophageal cancer (2024, November 15) retrieved 13 December 2024 from https://medicalxpress.com ...

Studies have demonstrated the efficacy of perioperative chemotherapy for treating esophageal adenocarcinoma as well as trimodality therapy for managing esophageal cancer, but survival outcomes ...

A study published inClinical Cancer Research found that in patients with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and immunotherapy made ...

Immunotherapy, a form of cancer treatment that harnesses the ... approved for various GI cancers including colorectal, ...

The pace at which medical advancements are taking place in the field of immunotherapy is staggering. Immunotherapy harnesses a patient’s own immune system to attack their cancer, and The Ottawa ...

A study published inClinical Cancer Research found that in patients with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and immunotherapy made ...

Surgery and radiation therapy are important for the treatment of GBM, and chemotherapy is helpful ... we realized that survivin-targeted immunotherapy had great potential to help patients with ...

Gastrointestinal cancers, including stomach, liver, esophageal ... including surgery, chemotherapy, radiation therapy and immunotherapy, among others. Although immunotherapy drugs for ...

Zaidi said the five-year survival rate for patients with advanced esophageal cancer is typically less than 20%. With the experimental doublet immunotherapy ... I went to chemo for seven weeks ...